A preliminary estimation of tissue factor pathway inhibitor
(TFPI) and protein C in patients with intracranial tumors

Rość, Danuta; Grabarczyk, Ewa; Bierwagen, Maciej; Wierciński, Marcin; Góralczyk, Krzysztof; Haor, Beata; Ruszkowska-Ciastek, Barbara

doi:10.17219/acem/67760

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A majority of our intracranial patient population underwent free flap cranial reconstruction after meningioma resection. Meningiomas, despite not containing glial tissue, have been found to exhibit similarly increased levels of TF as intraparenchymal tumors 30 . Ishimaru et al found the level of TF expression to correlate with the proliferative ability of a meningioma, with increased expression in higher grade tumors 28 .…”

Section: Discussionmentioning

confidence: 99%

“…Meningiomas, despite not containing glial tissue, have been found to exhibit similarly increased levels of TF as intraparenchymal tumors. 30 Ishimaru et al found the level of TF expression to correlate with the proliferative ability of a meningioma, with increased expression in higher grade tumors. 28 Similar to intraparenchymal tumor resection, D dimer, and fibrin degradation levels have been reported to rise during meningioma surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Perioperative Hypercoagulability in Free Flap Reconstructions Performed for Intracranial Tumors

et al. 2022

View full text Add to dashboard Cite

Objective(s): Patients with intracranial tumors have a higher risk of thromboembolic events. This risk increases at the time of surgical intervention. We have noted an anecdotal increase in perioperative flap thrombosis in patients undergoing free tissue transfer for intracranial tumor resection. This study aims to formally evaluate this risk.Methods: A multi-institutional retrospective chart review was performed of patients who underwent free tissue transfer for scalp/cranial reconstruction. Perioperative thrombosis and free flap outcomes were evaluated.Results: The 209 patients who underwent 246 free tissue transfers were included in the study. The 28 free flap scalp reconstructions were associated with intracranial tumors, 19 were performed following composite cranial resections with associated dural resection/reconstruction, and 199 were performed in the absence of intracranial tumors (control group). There was a significantly higher incidence of perioperative flap thrombosis in the intracranial tumor group (11/28, 39%) when compared to controls (38/199, 19%) (p = 0.0287). This was not seen when scalp tumors extended to the dura alone (4/19, 21%, p = 0.83). Therapeutic anticoagulation used for perioperative thrombosis (defined as intraoperative or in the immediate postoperative phase up to 5 days) was associated with a lower risk of flap failure, although this was not statistically significant (p = 0.148). Flap survival rates were equivalent between flaps performed for intracranial pathology (93.3%) and controls (95%).Conclusion: There is an increase in perioperative flap thrombosis in patients with intracranial tumors undergoing free tissue scalp reconstruction. Anticoagulation appears to mitigate this risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Perioperative Hypercoagulability in Free Flap Reconstructions Performed for Intracranial Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

BackgroundGliomas are the most common and aggressive tumors of the central nervous system. A robust and widely used blood-based biomarker for glioma has not yet been identified. In recent years, a plethora of new research on blood-based biomarkers for glial tumors has been published. In this review, we question which molecules, including proteins, nucleic acids, circulating cells, and metabolomics, are most promising blood-based biomarkers for glioma diagnosis, prognosis, monitoring and other purposes, and align them to the seminal processes of cancer.MethodsThe Pubmed and Embase databases were systematically searched. Biomarkers were categorized in the identified biomolecules and biosources. Biomarker characteristics were assessed using the area under the curve (AUC), accuracy, sensitivity and/or specificity values and the degree of statistical significance among the assessed clinical groups was reported.Results7,919 references were identified: 3,596 in PubMed and 4,323 in Embase. Following screening of titles, abstracts and availability of full-text, 262 articles were included in the final systematic review. Panels of multiple biomarkers together consistently reached AUCs >0.8 and accuracies >80% for various purposes but especially for diagnostics. The accuracy of single biomarkers, consisting of only one measurement, was far more variable, but single microRNAs and proteins are generally more promising as compared to other biomarker types.ConclusionPanels of microRNAs and proteins are most promising biomarkers, while single biomarkers such as GFAP, IL-10 and individual miRNAs also hold promise. It is possible that panels are more accurate once these are involved in different, complementary cancer-related molecular pathways, because not all pathways may be dysregulated in cancer patients. As biomarkers seem to be increasingly dysregulated in patients with short survival, higher tumor grades and more pathological tumor types, it can be hypothesized that more pathways are dysregulated as the degree of malignancy of the glial tumor increases. Despite, none of the biomarkers found in the literature search seem to be currently ready for clinical implementation, and most of the studies report only preliminary application of the identified biomarkers. Hence, large-scale validation of currently identified and potential novel biomarkers to show clinical utility is warranted.

show abstract

A preliminary estimation of tissue factor pathway inhibitor (TFPI) and protein C in patients with intracranial tumors

Abstract: Background. In patients with intracranial tumors, hypercoagulability is observed due to brain tissue and tumor cells being the source of tissue factor.

Cited by 2 publications

References 27 publications

Perioperative Hypercoagulability in Free Flap Reconstructions Performed for Intracranial Tumors

Perioperative Hypercoagulability in Free Flap Reconstructions Performed for Intracranial Tumors

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

Contact Info

Product

Resources

About